Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP. Issue 5 (15th April 2020)

• Record Type: Journal Article
• Authors: Kang, Junho; Chae, Heejung; Hong, Jung Yong; Yoon, Dok Hyun; Kim, Shin; Park, Jung Sun; Lee, Sang Wook; Park, Chan Sik; Ryu, Jin-Sook; Huh, Jooryung; Suh, Cheolwon
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 5(2020)
• Page Start: 1119
• Page End: 1125
• Publication Date: 2020-04-15
• Subjects: DLBCL -- R-CHOP -- late relapse; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2019.1709831
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The distinct clinical characteristics of patients at diagnosis of diffuse large B-cell lymphoma (DLBCL), who experience a late relapse compared with those who relapse early, require reappraisal in the era of R-CHOP. Data from the lymphoma registry of the Asan Medical Center between 2002 and 2015 were retrospectively reviewed. Among 846 DLBCL patients treated with first-line R-CHOP and achieved complete response, 169 (20%) relapsed, occurring late (>2 years) in 51 (6%). Compared with early relapses, late relapses were associated with a lower International Prognostic Index score ( p =.001), lower incidence of B-symptoms ( p =.004), lower lactate dehydrogenase ( p =.001), lower stage (I–II; p =.001), and the median overall survival from relapse was significantly longer (2.4 vs. 1.0 years, p =.001). Patients with a late relapse who responded to salvage chemotherapy and received autologous stem-cell transplantation, had higher 5-year survival rate (55.4% vs. 20.2%). Time of relapse and LDH level were independent prognostic factors affecting survival.